Search
Nemiralisib
go.drugbank.com/drugs/DB16253InvestigationalNemiralisib is under investigation in clinical trial NCT03345407 (Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)).
Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingPaltusotine
go.drugbank.com/drugs/DB16277ApprovedInvestigationalhormone (GH) and decreases the production of growth-promoting insulin-like growth factor 1 (IGF-1). ā¦ Paltusotine is a selective somatostatin receptor agonist: It mimics the biological actions of endogenous somatostatin, which activates the somatostatin 2 receptor (SST2) to block the secretion of growth
Categories: MATE 1 Inhibitors, MATE 2 InhibitorsCipepofol
go.drugbank.com/drugs/DB16295ApprovedInvestigationalGABA-A receptors, similar to the previously approved [propofol]. ā¦ [L63931] Cipepofol is approved in the United States for induction of general anesthesia in adults undergoing surgery, an approval Haisco announced on June 1, 2026.
Rezafungin
go.drugbank.com/drugs/DB16310ApprovedInvestigationalRezafungin has a half-life higher than 130 hours and can be administered once a week instead of daily. ā¦ [A258393,L45633] Unlike other echinocandins such as [caspofungin] and [micafungin], rezafungin has longāacting pharmacokinetics and a high stability that allows for it to have long dosing intervals maintaining
Synonyms: Echinocandin B, 1-((4R,5R)-4-hydroxy-N2-((4''-(pentyloxy)(1,1':4',1''-terphenyl)-4-yl)carbonyl)-5-(2-(trimethylammonio)ethoxy)-l-ornithine)-4-((4S)-4-hydroxy-4-(4-hydroxyphenyl)-l-allothreonine)-Categories: Heterocyclic Compounds, 1-RingSepiapterin
go.drugbank.com/drugs/DB16326ApprovedInvestigationalSepiapterin is a small molecule activator of phenylalanine hydroxylase (PAH) used to reduce phenyalanine levels in patients with phenylketonuria. ā¦ It is a natural precursor of the enzymatic co-factor tetrahydrobiopterin (BH4), which activates PAH and helps reduce blood phenylalanine levels by enhancing the conformational stability of misfolded PAH
Synonyms: L-sepiapterinCategories: Heterocyclic Compounds, 2-RingMobocertinib
go.drugbank.com/drugs/DB16390ApprovedInvestigationalWithdrawnMobocertinib is a kinase inhibitor targeted against human epidermal growth factor receptor (EGFR). ā¦ It is used specifically in the treatment of non-small cell lung cancer (NSCLC) caused by exon 20 insertion mutations in the _EGFR_ gene,[L38368] which are typically associated with a poorer prognosis (
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsFosdenopterin
go.drugbank.com/drugs/DB16628ApprovedIn 2009 a recombinant, E. coli-produced cPMP was granted orphan drug designation by the FDA, becoming the first therapeutic option for patients with MoCD type A. ā¦ [A230088] Signs and symptoms begin shortly after birth and are caused by a build-up of toxic sulfites resulting from a lack of SOX activity.
Synonyms: C(PMP)Categories: MATE 1 Substrates, MATE 2 InhibitorsSerdexmethylphenidate
go.drugbank.com/drugs/DB16629Approved[L32298, L32323] Serdexmethylphenidate was granted FDA approval on March 2, 2021, and is currently marketed as a combination capsule with [dexmethylphenidate] under the trademark AZSTARYSā¢ by KemPharm ā¦ [A230698, A230708] Serdexmethylphenidate is a prodrug of the CNS stimulant [dexmethylphenidate], a common first-line treatment for ADHD, that is combined with [dexmethylphenidate] to provide extended plasma
KW-2450 free base
go.drugbank.com/drugs/DB16637InvestigationalCategories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingReltecimod
go.drugbank.com/drugs/DB16687InvestigationalReltecimod is under investigation in clinical trial NCT02469857 (Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections).
Synonyms: D-alanyl-L-seryl-L-prolyl-L-methionyl-L-leucyl-L-valyl-L-alanyl-L-tyrosyl-L-aspartyl-D-alanineCategories: Antigens, Differentiation, T-Lymphocyte, Costimulatory and Inhibitory T-Cell Receptors